Agenus Revenue and Competitors
Estimated Revenue & Valuation
- Agenus's estimated annual revenue is currently $35M per year.
- Agenus's estimated revenue per employee is $85,995
- Agenus's total funding is $271.1M.
Employee Data
- Agenus has 407 Employees.
- Agenus grew their employee count by 24% last year.
Agenus's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman & CEO | Reveal Email/Phone |
2 | Chief Commercial Transactions Officer & Acting General Counsel | Reveal Email/Phone |
3 | Chief People Officer (CHRO) | Reveal Email/Phone |
4 | Chief Corporate Affairs Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | VP, GMA, Chief Staff | Reveal Email/Phone |
7 | Chief Medical Affairs Officer | Reveal Email/Phone |
8 | VP, Research | Reveal Email/Phone |
9 | VP Molecular and Information Science | Reveal Email/Phone |
10 | Head Investor Relations & Corporate Development | Reveal Email/Phone |
Agenus Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Agenus?
Antigenics,Inc. is developing treatments for cancers, serius infectious diseases,autoimmune disorders and degenerative disorders, using the Company's proprietary technologies to program the immune system and improve quality of life. These products de immunotherapeutics basedon a specific class of heat shock proteins (HSPs), which activate powerful cellular immune responses, and St products,including QS-21, which activates superior antibody responses. At year-end 2000, the Company was evaluating its lead HSP-ased immunotherapeutic, Oncophage, in an international multi-center Phase III cancer, and in five additional cancer indications in ms and partnerships, the Company was also testing its Stimulon-based products in 11 Phase III and Phase II clinical trials for cancer, several infectious diseases and degenerative disorders.
keywords:N/A
$271.1M
Total Funding
407
Number of Employees
$35M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Agenus News
A premium-rich buyout is sparking a rally among experimental cancer companies today. Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics...
Despite its successful collaborations, Agenus has never caught on with investors and is now trading near its all time lows. Agenus' recent Q4,...
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to...
Other Companies in Lexington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $137.7M | 408 | 9% | N/A |
#2 | $19.8M | 418 | 26% | $400M |
#3 | $7.5M | 419 | N/A | N/A |
#4 | $15M | 429 | 4% | N/A |
#5 | $140.7M | 443 | 4% | N/A |